Skip Navigation
Skip to contents
Filter

ARTICLE TYPE

PUBLICATION DATE

9 results
Display

Response to the Editor

Ohta H, Uenishi K, Shiraki M

  • Osteoporos Sarcopenia.
  • 2017 Mar;3(1):60-61.
  • doi: 10.1016/j.afos.2017.01.004
No abstract available.
Letter to the Editor

Park YK

  • Osteoporos Sarcopenia.
  • 2017 Mar;3(1):59-59.
  • doi: 10.1016/j.afos.2017.01.003
No abstract available.
Associations between serum 25-hydroxyvitamin D3 level and skeletal muscle mass and lower limb muscle strength in Japanese middle-aged subjects

Kuwabara A, Tsugawa N, Kondo H, Ao M, Fujiwara H, Hosokawa N, Matsumoto , Tanaka K, Nakano T

  • Osteoporos Sarcopenia.
  • 2017 Mar;3(1):53-58.
  • doi: 10.1016/j.afos.2017.02.002
OBJECTIVES: One of the important risk factors of falling is decreased muscle mass and muscle strength. Recently, there has been an increasing concern on the role of vitamin D in...
Bone turnover rate and bone formation/resorption balance during the early stage after switching from a bone resorption inhibitor to denosumab are predictive factors of bone mineral density change

Nakatoh S

  • Osteoporos Sarcopenia.
  • 2017 Mar;3(1):45-52.
  • doi: 10.1016/j.afos.2016.12.001
OBJECTIVES: This study aimed to investigate the correlation between bone mineral density (BMD) and the turnover rate [√(MoMf²+ MoMr²), multiple of median formation (MoMf) was calculated as bone-specific alkaline phosphatase...
Comparison of effectiveness and safety of ibandronate and minodronate combined with eldecalcitol in primary osteoporosis of women: A 1-year follow-up study

Tanaka M, Nakamura Y, Itoh S, Kato Y

  • Osteoporos Sarcopenia.
  • 2017 Mar;3(1):37-44.
  • doi: 10.1016/j.afos.2016.12.002
OBJECTIVES: This is an open labeled and retrospective cohort study which compared the effectiveness and safety of ibandronate (IBN) and minodronate (MIN) combined with eldecalcitol (ELD) in primary osteoporosis of...
Favorable effects of skeletal muscle on bone are distinguished according to gender and skeletal sites

Kim KM, Lee EY, Lim S, Jang HC, Kim CO

  • Osteoporos Sarcopenia.
  • 2017 Mar;3(1):32-36.
  • doi: 10.1016/j.afos.2016.11.001
OBJECTIVES: The aim of this study was to investigate associations between skeletal muscle mass and bone mineral density according to gender and skeletal sites. METHODS: Using the data from Korean National...
Osteoporosis prevention and osteoporosis exercise in community-based public health programs

Nguyen VH

  • Osteoporos Sarcopenia.
  • 2017 Mar;3(1):18-31.
  • doi: 10.1016/j.afos.2016.11.004
Osteoporosis is a serious public health concern worldwide, and community-based public health programs that increase osteoporosis preventive behaviors are ideal to combat this major public health issue. A review of...
Denosumab for the treatment of osteoporosis

McClung MR

  • Osteoporos Sarcopenia.
  • 2017 Mar;3(1):8-17.
  • doi: 10.1016/j.afos.2017.01.002
Denosumab, a specific inhibitor of RANK ligand, is a novel therapy for postmenopausal osteoporosis and related disorders. An extensive clinical development program has evaluated the clinical efficacy and safety of...
An update of the Malaysian Clinical Guidance on the management of glucocorticoid-induced osteoporosis, 2015

Yeap SS, Hew FL, Damodaran , Chee W, Lee JK, Goh EM, Chan SP, The Malaysian Osteoporosis Society Committee Working Group for the Clinical Guidance on the Management of Osteoporosis, 2015

  • Osteoporos Sarcopenia.
  • 2017 Mar;3(1):1-7.
  • doi: 10.1016/j.afos.2017.01.001
OBJECTIVES: This Clinical Guidance is aimed to help practitioners assess, diagnose and manage their patients with glucocorticoid-induced osteoporosis (GIO), using the best available evidence. METHODS: A literature search using PubMed (MEDLINE)...

Go to Top

Copyright © 2020 by Korean Association of Medical Journal Editors. All rights reserved.     E-mail: koreamed@kamje.or.kr